Currently out of the existing stock ratings of Dane Leone, 109 are a BUY (83.85%), 19 are a HOLD (14.62%), 2 are a SELL (1.54%).

Dane Leone

Work Performance Price Targets & Ratings Chart

Analyst Dane Leone, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 55.5% that have a potential upside of 35.22% achieved within 225 days.

Dane Leone’s has documented 227 price targets and ratings displayed on 32 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on XLO, Xilio Development at 08-Nov-2024.

Wall Street Analyst Dane Leone

Analyst best performing recommendations are on NKTX (NKARTA ).
The best stock recommendation documented was for BBIO (BRIDGEBIO PHARMA) at 12/28/2021. The price target of $17 was fulfilled within 6 days with a profit of $3.57 (26.58%) receiving and performance score of 44.3.

Average potential price target upside

of $292.8 (40.26%) on BLUE (BLUEBIRD BIO).
of $92.06 (19.36%) on REGN (REGENERON PHARMACEUTICALS).
of $75.33 (42.62%) on AMGN (AMGEN).

ADVM Adverum Biotechnologies ALLO Allogene Therapeutics BLUE Bluebird bio BPMC Blueprint Medicines Corp CYTK Cytokinetics GTHX G1 Therapeutics OCUL Ocular Therapeutix REGN Regeneron Pharmaceuticals RGNX Regenxbio SAGE Sage Therapeutic SLP Simulations Plus TARS Tarsus Pharmaceuticals BRKR Bruker GLPG Galapagos NV ADR BMY Bristol-Myers Squibb Company CRIS Curis NKTX Nkarta CMPX Compass Therapeutics XNCR Xencor SGEN Seagen AMGN Amgen AYLA Ayala Pharmaceuticals BBIO BridgeBio Pharma JNJ Johnson & Johnson LIAN LianBio ADR RLAY Relay Therapeutics VYGR Voyager Therapeutics XLO Xilio Development ALR Alerislife CELG Celgene ILMN Illumina MGNX MacroGenics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Caufield (HC WAINWRIGHT)